Sugi Predict

Sugi Predict / Compounds / SCHEMBL11968633

SCHEMBL11968633

SCHEMBL11968633

CN(C)C(=O)C(O)c1cncc(-c2cnc3[nH]cc(-c4ccc(N(C)C)cc4)c3c2)c1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MAPK8 P45983 1/20 0.54
▸ MAPK9 P45984 1/20 0.54
▸ MAPK10 P53779 1/20 0.54
▸ MAP3K11 Q16584 3/20 0.54
▸ NTRK1 P04629 2/20 0.50
▸ SGK1 O00141 5/20 0.48
▸ CLK1 P49759 3/20 0.46
▸ DYRK1A Q13627 3/20 0.46
▸ DYRK2 Q92630 3/20 0.46
▸ DYRK1B Q9Y463 3/20 0.46
▸ ABL1 P00519 1/20 0.46
▸ AXL P30530 3/20 0.46
▸ CAMKK2 Q96RR4 2/20 0.46
▸ MAP4K1 Q92918 1/20 0.44
▸ KIT P10721 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11968617 0.91 MAP3K11 (0.52) MAP3K11NTRK1SGK1CLK1DYRK1A
SCHEMBL11968615 0.90 MAP3K11 (0.51) MAP3K11NTRK1SGK1CLK1DYRK1A
SCHEMBL11968626 0.90 CLK1 (0.53) MAP3K11SGK1CLK1DYRK1ADYRK2
SCHEMBL14041541 0.90 NTRK1 (0.55) MAP3K11NTRK1SGK1CLK1DYRK1A
SCHEMBL11968623 0.90 SGK1 (0.56) MAPK8MAPK9MAP3K11NTRK1SGK1
SCHEMBL11968628 0.90 NTRK1 (0.56) MAP3K11NTRK1ABL1AXLKIT
SCHEMBL11968643 0.90 NTRK1 (0.60) MAP3K11NTRK1ABL1AXLKIT
SCHEMBL11968629 0.89 MAP3K11 (0.50) MAP3K11NTRK1SGK1CLK1DYRK1A
SCHEMBL11968618 0.89 DYRK1A (0.55) MAPK9MAP3K11NTRK1SGK1DYRK1A
SCHEMBL11968634 0.89 MAP3K11 (0.59) MAPK8MAPK9MAP3K11NTRK1SGK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242280-B2 morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia SGX PHARMACEUTICALS, INC. (US) 2012-08-14 — — US disclosed
US-8242280-B2 morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia SGX PHARMACEUTICALS, INC. (US) 2012-08-14 — — US disclosed
US-20080261921-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-23 — — US disclosed
US-20080261921-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-23 — — US disclosed
WO-2008124848-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261921-A1 FUSED RING HETEROCYCLE KINASE MODULATORS MAP3K20, MAP3K19, MAP4K2 MAPK8 258/4885MAPK9 246/4885MAPK10 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.